Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 05/04/26 | 8-K | Current report |
|
  |
116 |
| 05/04/26 | 424B5 | Prospectus [Rule 424(b)(5)] |
|
79 | |
| 05/04/26 | 8-K | Current report |
|
|
4 |
| 04/28/26 | ARS | Annual Report to Security Holders |
|
180 | |
| 04/28/26 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
|
3 | |
| 04/28/26 | DEF 14A | Definitive proxy statements |
|
|
65 |
| 04/20/26 | 8-K | Current report |
|
|
53 |
| 04/17/26 | PRE 14A | Preliminary proxy statement not related to a contested matter or merger/acquisition |
|
|
67 |
| 03/23/26 | S-8 | Securities to be offered to employees in employee benefit plans |
|
|
16 |
| 03/23/26 | 10-K | Annual report [Section 13 and 15(d), not S-K Item 405] |
|
|
221 |
